Chetan Nambiar
A5063005259- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cytokine Signaling Pathways and Interactions
- MicroRNA in disease regulation
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Pancreatic and Hepatic Oncology Research
- Genomics, phytochemicals, and oxidative stress
Dana-Farber Cancer Institute
2023-2025
University of Chicago
2025
Dana-Farber Brigham Cancer Center
2024
Harvard University
2024
University of California, San Diego
2018
Abstract Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. Colorectal cohorts genomic profiling were used to identify cases [Dana-Farber, n = 47/2,729 (1.7%); FMI, 1857/49,839 (3.7%)]. Outcomes patients receiving HER2-directed therapies reported (Dana-Farber, 9; Flatiron Health-Foundation clinicogenomic...
473 Background: HER2 gene dosage (i.e. level of amplification) and heterogeneity are key prognostic variables for HER2+ gastroesophageal adenocarcinoma (GEA), yet no standardized approach to test these in routine clinical use exists. Here we modify the analytical pipeline FISH quantitatively estimate correlate them with outcomes. Methods: Patients metastatic GEA who received trastuzumab-based therapy between 2011-2024 at Dana-Farber Cancer Institute had available pre-treatment tissue...
72 Background: Incidence of early-onset (ages 18-49) gastrointestinal cancers is alarmingly increasing. To assess unmet needs in health-related quality life (HRQoL), we conducted this pilot study using PRO measures patients with EOGIC. Methods: Patients ages 18-49 any GI cancer seen at our center during a clinic visit were invited to participate cross-sectional study. Validated tools PROMIS 29+2, GP5 from FACT-G, AYA Sexual Health Battery and Adult Neuro-QOL Cognitive Function short form...
199 Background: Anti-EGFR antibodies like cetuximab are ineffective in KRAS mutated (mt) colorectal cancer (CRC) due to constitutive activation of downstream pathways. Avutometinib is a first class, oral, novel, dual RAF/MEK inhibitor. In patient-derived xenograft models mt CRC, the combination an anti-EGFR antibody with avutometinib conferred stronger tumor growth inhibition than either agent alone. We present results from dose escalation phase (1b) ongoing 1b/2 trial evaluating plus...
4112 Background: The treatment of hepatocellular carcinoma (HCC), the third leading cause global cancer death, has significantly improved with advent immune checkpoint inhibitor regimens. Circulating tumor cells (CTCs) contain precursors metastasis and can be serially sampled while patients receive therapy. Quantification CTC dynamics during HCC therapy may yield early insight into systemic anticancer response profile. Methods: We used a commercially available microfluidic purification...
PURPOSE GI cancers commonly spread to the peritoneal cavity, particularly from primary adenocarcinomas of stomach and appendix. Peritoneal metastases are difficult visualize on cross-sectional imaging cause substantial morbidity mortality. The purpose this study was determine whether serial highly sensitive tumor-informed circulating tumor DNA (ctDNA) measurements could longitudinally track changes in disease burden inform clinical care. METHODS This a retrospective case series patients with...
<p>Supplementary Figure 6. Generation of HER2 overexpressing CRC cell lines with endogenous KRAS mutations.</p>
<div>AbstractPurpose:<p><i>ERBB2</i>-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic <i>RAS/RAF</i> alterations are not known.</p>Experimental Design:<p>Dana-Farber and Foundation Medicine Inc. Colorectal cohorts genomic profiling were used to identify <i>ERBB2</i>-amplified cases [Dana-Farber, <i>n</i> = 47/2,729 (1.7%); FMI, 1857/49,839...
<p>Supplementary Figure 3. Response and resistance to trastuzumab/lapatinib.</p>
<p>Supplementary Figure 4. RAS/RAF co-altered, HER2 amplified CRC reflects a unique genomic subset with intratumoral heterogeneity.</p>
<p>Supplementary Figure 2. HER2 amplification shows uniform expression in CRC.</p>
<p>Supplementary Figure 2. HER2 amplification shows uniform expression in CRC.</p>
<p>Supplementary Figure 5. LS180 and SW480 harbor endogenous hotspot mutations in KRAS.</p>
<div>AbstractPurpose:<p><i>ERBB2</i>-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic <i>RAS/RAF</i> alterations are not known.</p>Experimental Design:<p>Dana-Farber and Foundation Medicine Inc. Colorectal cohorts genomic profiling were used to identify <i>ERBB2</i>-amplified cases [Dana-Farber, <i>n</i> = 47/2,729 (1.7%); FMI, 1857/49,839...
<p>Supplementary Figure 6. Generation of HER2 overexpressing CRC cell lines with endogenous KRAS mutations.</p>
<p>Supplementary Methods</p>